References
Key articles
Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021 Dec 2;7(1):86. Abstract
Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109-29.Full text Abstract
Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies: a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017 Jul;17(4):322-8.Full text Abstract
Oldroyd AGS, Lilleker JB, Amin T, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022 May 5;61(5):1760-8.Full text Abstract
Reference articles
1. Khoo T, Lilleker JB, Thong BY, et al. Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2023 Nov;19(11):695-712. Abstract
2. Ashton C, Paramalingam S, Stevenson B, et al. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021 Jun;51(6):845-52.Full text Abstract
3. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec;76(12):1955-64.Full text Abstract
4. Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021 Dec 2;7(1):86. Abstract
5. Okiyama N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med. 2021 Apr 16;10(8):1725.Full text Abstract
6. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018 Apr 20;14(5):290-302. Abstract
7. Shah M, Shinjo SK, Day J, et al. Cardiovascular manifestations in idiopathic inflammatory myopathies. Clin Rheumatol. 2023 Oct;42(10):2557-75.Full text Abstract
8. Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990;17:1329-1334. Abstract
9. Medsger TA, Dawson WN Jr, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48:715-723. Abstract
10. Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol. 2004;18:331-344. Abstract
11. Dorph C, Lundberg IE. Idiopathic inflammatory myopathies - myositis. Best Pract Res Clin Rheumatol. 2002;16:817-832. Abstract
12. Vivekanandam V, Bugiardini E, Merve A, et al. Differential diagnoses of inclusion body myositis. Neurol Clin. 2020 Aug;38(3):697-710. Abstract
13. Oflazer PS, Deymeer F, Parman Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Acta Myol. 2011 Jun;30(1):34-6.Full text Abstract
14. Shelly S, Mielke MM, Mandrekar J, et al. Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology. 2021 May 25;96(21):e2653-61. Abstract
15. Day J, Otto S, Proudman S, et al. Dysregulated innate immune function in the aetiopathogenesis of idiopathic inflammatory myopathies. Autoimmun Rev. 2017 Jan;16(1):87-95. Abstract
16. Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev. 2012 Jan;11(3):203-6. Abstract
17. Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol. 2014 Dec;178(3):405-15.Full text Abstract
18. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015 Apr 30;372(18):1734-47. Abstract
19. Schiffenbauer A, Faghihi-Kashani S, O'Hanlon TP, et al. The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018 Dec;48(3):504-12.Full text Abstract
20. Carpenter S, Karpati G. Pathology of skeletal muscle. 2nd ed. New York, NY: Oxford University Press USA; 2001.
21. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology. 2006;66(2 suppl 1):S33-S38. Abstract
22. Chou SM. Inclusion body myositis: a chronic persistent mumps myositis? Hum Pathol. 1986;17:765-777. Abstract
23. Dalakas MC, Pezeshkpour GH, Gravell M, et al. Polymyositis associated with AIDS retrovirus. JAMA. 1986 Nov 7;256(17):2381-3. Abstract
24. Dalakas MC, Rakocevic G, Shatunov A, et al. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol. 2007;61:466-475. Abstract
25. Saud A, Naveen R, Aggarwal R, et al. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021 Jul 3;23(8):63.Full text Abstract
26. Kharouf F, Kenig A, Bohbot E, et al. Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience. Clin Exp Rheumatol. 2023 Mar;41(2):316-21. Abstract
27. Karpati G, Hilton-Jones D, Griggs RC. Disorders of voluntary muscle. 7th ed. Cambridge, UK: Cambridge University Press; 2001.
28. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov;28(4):891-916. Abstract
29. Caughey GE, Gabb GM, Ronson S, et al. Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population. JAMA Intern Med. 2018 Sep 1;178(9):1224-9.Full text Abstract
30. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol. 2008;59:872-880. Abstract
31. Close RM, Close LM, Galdun P, et al. Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies. Rheumatology (Oxford). 2021 Feb 1;60(2):692-8.Full text Abstract
32. Basharat P, Lahouti AH, Paik JJ, et al. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol. 2016 Jul 12;68(2):234-5.Full text Abstract
33. Hamada N, Maeda A, Takase-Minegishi K, et al. Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol. 2021;12:803410.Full text Abstract
34. Opinc-Rosiak AH, Makowska JS. Environmental exposures as risk factors for idiopathic inflammatory myopathies. J Autoimmun. 2023 Nov;140:103095.Full text Abstract
35. Shelly S, Triplett JD, Pinto MV, et al. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun. 2020;2(2):fcaa181.Full text Abstract
36. Monaghan M, Loh C, Jones S, et al. Inflammatory myositis secondary to anti-retroviral therapy in a child; case Rreport and review of the literature. J Neuromuscul Dis. 2021;8(6):1089-95. Abstract
37. Syrmou V, Liaskos C, Ntavari N, et al. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunol Res. 2023 Aug;71(4):537-46.Full text Abstract
38. Ferri C, Colaci M, Manzini CU, et al. Polymyositis following Pandemic Influenza A (H1N1) and 2009-10 Seasonal Trivalent Vaccines. Case Rep Rheumatol. 2012;2012:836930.Full text Abstract
39. Altman A, Szyper-Kravitz M, Shoenfeld Y. HBV vaccine and dermatomyositis: is there an association? Rheumatol Int. 2008 Apr;28(6):609-12. Abstract
40. Chinoy H, Adimulam S, Marriage F, et al. Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis. 2012 Jun;71(6):961-5.Full text Abstract
41. Okada S, Weatherhead E, Targoff IN, et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003 Aug;48(8):2285-93.Full text Abstract
42. Limaye V, Blumbergs P, Scott G et al. The epidemiology of dermatomyositis in South Australia. APLAR J. Rheumatol. 2007 May 15;10(2):94-100.
43. Svensson J, Arkema EV, Lundberg IE, et al. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology (Oxford). 2017 May 1;56(5):802-10.Full text Abstract
44. O'Hanlon T, Koneru B, Bayat E, et al. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis Rheum. 2004 Nov;50(11):3646-50.Full text Abstract
45. Selva-O'Callaghan A, Tura JM, Grau-Junyent JM, et al. Silicone gel filled breast implants and dermatomyositis. Clin Exp Rheumatol. 2004 May-Jun;22(3):376. Abstract
46. Limaye S, Limaye V. Clinical characteristics of myositis associated with graft-versus-host disease. Curr Rheumatol Rep. 2021 Apr 24;23(5):30. Abstract
47. Reed AM, McNallan K, Wettstein P, et al. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? J Immunol. 2004 Apr 15;172(8):5041-6.Full text Abstract
48. Chanbour H, Jiblawi A, Aboudalle A, et al. Association of silicosis and dermatomyositis: case report and literature review. Cureus. 2021 Nov;13(11):e19875.Full text Abstract
49. Christopher-Stine L, Plotz PH. Myositis: an update on pathogenesis. Curr Opin Rheumatol. 2004 Nov;16(6):700-6. Abstract
50. Rothwell S, Cooper RG, Lundberg IE, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. 2016 Aug;75(8):1558-66. Abstract
51. Rothwell S, Chinoy H, Lamb JA, et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis. 2019 Jul;78(7):996-1002.Full text Abstract
52. Rothwell S, Cooper RG, Lundberg IE, et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol. 2017 May;69(5):1090-9.Full text Abstract
54. Rothwell S, Amos CI, Miller FW, et al. Identification of novel associations and localization of signals in idiopathic inflammatory myopathies using genome-wide imputation. Arthritis Rheumatol. 2023 Jun;75(6):1021-7.Full text Abstract
55. Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018 Apr;77(4):602-11. Abstract
56. Chan SH, Bylstra Y, Teo JX, et al. Analysis of clinically relevant variants from ancestrally diverse Asian genomes. Nat Commun. 2022 Nov 5;13(1):6694.Full text Abstract
57. Dourado E, Bottazzi F, Cardelli C, et al. Idiopathic inflammatory myopathies: one year in review 2022. Clin Exp Rheumatol. 2023 Mar;41(2):199-213. Abstract
58. Lundberg IE, Miller FW, Tjärnlund A, et al. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med. 2016 Jul;280(1):39-51.Full text Abstract
59. Banker BQ. Dermatomyostis of childhood, ultrastructural alterations of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol. 1975;34:46-75. Abstract
60. Carpenter S, Karpati G, Rothman S, et al. The childhood type of dermatomyositis. Neurology. 1976;26:952-962. Abstract
61. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567. Abstract
62. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991 Nov 21;325(21):1487-98. Abstract
63. Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology. 2000;54:65-71. Abstract
64. Lindvall B, Dahlbom K, Henriksson KG, et al. The expression of adhesion molecules in muscle biopsies: the LFA-1/VLA-4 ratio in polymyositis. Acta Neurol Scand. 2003;107:134-141. Abstract
65. Snedden AM, Kellett KAB, Lilleker JB, et al. The role of protein aggregation in the pathogenesis of inclusion body myositis. Clin Exp Rheumatol. 2022 Feb;40(2):414-24. Abstract
66. Dalakas MC. Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006 Aug;2(8):437-47. Abstract
67. Rönnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013 Mar;25(2):248-53. Abstract
68. Arshanapalli A, Shah M, Veerula V, et al. The role of type I interferons and other cytokines in dermatomyositis. Cytokine. 2015 Jun;73(2):319-25. Abstract
69. Zampieri S, Ghirardello A, Iaccarino L, et al. Polymyositis-dermatomyositis and infections. Autoimmunity. 2006 May;39(3):191-6. Abstract
70. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010 May;11(5):373-84.Full text Abstract
71. Baccala R, Hoebe K, Kono DH, et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007 May;13(5):543-51. Abstract
72. Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5(2):109-29.Full text Abstract
73. Preuße C, Goebel HH, Held J, et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol. 2012 Dec;181(6):2161-71.Full text Abstract
74. Oldroyd AGS, Callen JP, Chinoy H, et al. International guideline for idiopathic inflammatory myopathy-associated cancer screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023 Dec;19(12):805-17.Full text Abstract
75. Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010 Apr;62(4):465-72.Full text Abstract
76. Medical Research Council. Aids to the examination of the peripheral nervous system. 1976 [internet publication].Full text
77. Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies: a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017 Jul;17(4):322-8.Full text Abstract
78. Lundberg I. Polymyositis and dermatomyositis. In: Bijlsma J, ed. Eular textbook on rheumatic diseases. 1st ed. London: BMJ Group; 2012: 568-93.
79. Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024 Jan;20(1):48-62. Abstract
80. Chua CG, Low JZ, Lim WY, et al. Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore. Ann Acad Med Singap. 2022 Dec;51(12):755-65.Full text Abstract
81. Dion E, Chérin P. Use of muscular MRI in inflammatory myopathies [in French]. Rev Med Interne. 2004;25:435-441. Abstract
82. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung dsease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res (Hoboken). 2024 Aug;76(8):1070-82.Full text Abstract
83. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112:727-747. Abstract
84. Badrising UA, Maat-Schieman ML, van Houwelingen JC, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol. 2005;252:1448-1454. Abstract
85. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016 Jul;280(1):8-23.Full text Abstract
86. Motomura K, Yamashita H, Yamada S, et al. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study. Rheumatol Int. 2019 Oct;39(10):1733-9. Abstract
87. Engel A, Franzini-Armstrong C. Myology: basic and clinical. 3rd ed. New York: McGraw-Hill, Medical Publishing Division; 2004.
88. Al-Nahhas A, Jawad AS. PET/CT imaging in inflammatory myopathies. Ann N Y Acad Sci. 2011 Jun;1228:39-45. Abstract
89. Fan X, Rouleau GA. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy. Can J Neurol Sci. 2003;30:8-14. Abstract
90. Rose MR; ENMC IBM Working Group. 188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, Naarden, the Netherlands. Neuromuscul Disord. 2013 Dec;23(12):1044-55.Full text Abstract
91. The Myositis Association. Diagnostic criteria for necrotizing myopathy [internet publication].Full text
92. Colak A, Benli K, Dönmez T, et al. Papillary carcinoma of the sphenoid sinus associated with sphenoid sinus abscess presenting as cavernous sinus syndrome. A case report. J Clin Neuroophthalmol. 1990 Mar;10(1):18-20. Abstract
93. Oldroyd AGS, Lilleker JB, Amin T, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2022 May 5;61(5):1760-8.Full text Abstract
94. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024 Aug;76(8):1182-200.Full text Abstract
95. Lim J, Eftimov F, Verhamme C, et al. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology (Oxford). 2021 Apr 6;60(4):1784-92.Full text Abstract
96. Lee H, Chung SJ, Kim SH, et al. Treatment outcomes of infectious and non-infectious acute exacerbation of myositis-related interstitial lung disease. Front Med (Lausanne). 2021;8:801206.Full text Abstract
97. Wiala A, Vujic I, Richter L, et al. Dermatomyositis requires long-term treatment with combined immunosuppressive and immunoglobulin therapy. J Dtsch Dermatol Ges. 2021 Mar;19(3):456-8. Abstract
98. Hoff LS, de Souza FHC, Miossi R, et al. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis. Rheumatology (Oxford). 2022 Apr 11;61(4):1579-88.Full text Abstract
99. Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve. 2006;34:284-291. Abstract
100. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129-137. Abstract
101. Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011 Oct;24(5):457-62. Abstract
102. Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics. 2008;5:548-557. Abstract
103. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-324. Abstract
104. Fasano S, Gordon P, Hajji R, et al. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017 Jan;56(1):26-36.Full text Abstract
105. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010 Sep;62(9):1328-34.Full text Abstract
106. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007 Sep;34(9):1864-8. Abstract
107. Ge Y, Li S, Tian X, et al. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol. 2021 Jun;40(6):2311-7. Abstract
108. Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol. 2003 Oct;16(5):569-75. Abstract
109. Tjärnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018 Jan;77(1):55-62. Abstract
110. Connolly CM, Gupta L, Fujimoto M, et al. Idiopathic inflammatory myopathies: current insights and future frontiers. Lancet Rheumatol. 2024 Feb;6(2):e115-27. Abstract
111. Paik JJ, Shneyderman M, Gutierrez-Alamillo L, et al. Long-term extension study of tofacitinib in refractory dermatomyositis. Arthritis Rheumatol. 2022 Feb;74(2):371-2. Abstract
112. ClinicalTrials.gov. Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD). ClinicalTrials.gov Identifier: NCT04972760. Mar 2024 [internet publication].Full text
113. ClinicalTrials.gov. Baricitinib in the treatment of new-onset juvenile dermatomyositis (MYOCIT) (MYOCIT). ClinicalTrials.gov Identifier: NCT05524311. Jan 2024 [internet publication].Full text
114. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019 Jul 18;381(3):291-3. Abstract
115. Shirai T, Machiyama T, Sato H, et al. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clin Exp Rheumatol. 2023 Mar;41(2):291-300. Abstract
116. Fan L, Lyu W, Liu H, et al. A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with Ttofacitinib or tacrolimus. J Rheumatol. 2022 Dec;49(12):1356-64.Full text Abstract
117. Peter HH, Ochs HD, Cunningham-Rundles C, et al. Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020 Sep;146(3):479-91.e5.Full text Abstract
118. ClinicalTrials.gov. A study of nipocalimab in participants with active idiopathic inflammatory myopathies (SPIREA). ClinicalTrials.gov Identifier: NCT05379634. Jul 2024 [internet publication].Full text
119. ClinicalTrials.gov. A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammatory myopathy (ALKIVIA+). ClinicalTrials.gov Identifier: NCT05979441. Jul 2024 [internet publication].Full text
120. ClinicalTrials.gov. A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy. (ALKIVIA). ClinicalTrials.gov Identifier: NCT05523167. Jul 2024 [internet publication].Full text
121. Wilfong EM, Aggarwal R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Ther Adv Musculoskelet Dis. 2021;13:1759720X211060907.Full text Abstract
122. Li T, Guo L, Chen Z, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. 2016 Sep 12;6:33226.Full text Abstract
123. Liang J, Cao H, Yang Y, et al. Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study. Front Med (Lausanne). 2021;8:626953.Full text Abstract
124. Goel N, Needham M, Soler-Ferran D, et al. POS1342 Depletion of KLRG1+ T cells in a first-in-human clinical trial of ABC008 in inclusion body myositis (IBM). Nature. 2017 Oct 19;550(7676):407-10.
125. Benveniste O, Hogrel JY, Belin L, et al. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatol. 2021 Jan;3(1):e40-8. Abstract
126. Lyu X, Gupta L, Tholouli E, et al. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. Rheumatology (Oxford). 2024 May 2;63(5):1206-16.Full text Abstract
127. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023 Nov 25;402(10416):2034-44. Abstract
128. ClinicalTrials.gov. IMPT-514 in systemic lupus erythematosus, anca-associated vasculitis, and idiopathic inflammatory myopathy. ClinicalTrials.gov Identifier: NCT06462144. Jul 2024 [internet publication].Full text
129. American College of Rheumatology. 2022 American College of Rheumatology (ACR) guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Feb 2023 [internet publication].Full text
130. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21(2 suppl 1):S57-S107. Abstract
131. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008 Sep;15(9):893-908.Full text Abstract
132. Dobloug GC, Svensson J, Lundberg IE, et al. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis. 2018 Jan;77(1):40-7. Abstract
133. Sultan SM, Ioannou Y, Moss K, et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford). 2002;41:22-26.Full text Abstract
134. Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-2237. Abstract
135. So J, So H, Wong VT, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology (Oxford). 2022 Nov 2;61(11):4437-44.Full text Abstract
136. Limaye V, Hakendorf P, Woodman RJ, et al. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J. 2012 Feb;42(2):191-8.Full text Abstract
137. Briani C, Doria A, Sarzi-Puttini P, et al. Update on idiopathic inflammatory myopathies. Autoimmunity. 2006;39:161-170. Abstract
138. de Merieux P, Verity MA, Clements PJ, et al. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis. Arthritis Rheum. 1983 Aug;26(8):961-8. Abstract
139. Kagen LJ, Hochman RB, Strong EW. Cricopharyngeal obstruction in inflammatory myopathy (polymyositis/dermatomyositis). Report of three cases and review of the literature. Arthritis Rheum. 1985;28:630-636. Abstract
140. Madan V, Chinoy H, Griffiths CE, et al. Defining cancer risk in dermatomyositis: part I. Clin Exp Dermatol. 2009 Jun;34(4):451-5. Abstract
141. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001 Jun 19;134(12):1087-95. Abstract
142. Wakata N, Kurihara T, Saito E, et al. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002 Nov;41(11):729-34. Abstract
143. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001 Jan 13;357(9250):96-100. Abstract
144. Callen JP. Relation between dermatomyositis and polymyositis and cancer. Lancet. 2001 Jan 13;357(9250):85-6. Abstract
145. Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle Nerve. 2001 Nov;24(11):1562-6. Abstract
Use of this content is subject to our disclaimer